Cross-Sector entity
All 1 tracked stories fall under one category: pharma. SAB Biotherapeutics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention DiversitAb, all published on March 17, 2026.
1 verified story tracked
Last mentioned: Mar 17, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. SAB Biotherapeutics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention DiversitAb, all published on March 17, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering DiversitAb. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen Downgrade
SABS and SSSS both receive Sell ratings from Wall Street Zen.
SAB-142 Clinical Progress
SAB Biotherapeutics continues enrollment for its Phase 1/2 trial in Type 1 Diabetes.
Strategic Pivot
Company shifts focus from infectious diseases to immunology and chronic conditions.
Wall Street Zen has downgraded SAB Biotherapeutics (SABS) and its investor SURO Capital (SSSS) to Sell ratings. The move signals increasing caution regarding SAB's clinical-stage polyclonal antibody platform and the broader venture-backed biotech ecosystem.
Source: tickerreport.com · tickerreport.com
